TMB-003

TMB-003 is a proprietary, locally administered formulation of **sitaxsentan**, developed for the treatment of scleroderma, especially systemic sclerosis and localized scleroderma[1][5]. Sitaxsentan is a highly selective **endothelin-A receptor antagonist** originally pursued in oral form for pulmonary arterial hypertension but withdrawn from global markets due to liver toxicity. TMB-003 is being developed as a topical or locally applied therapy to avoid systemic side effects, acting by reducing collagen production and inhibiting fibroblast migration in affected skin[1][5]. Timber Pharmaceuticals holds orphan drug designation from the FDA for TMB-003 in systemic sclerosis, and the drug is currently in preclinical development[1][5].

Brand names

TMB-003TMB003TMB 003

Other names

sitaxsentan (locally administered formulation)locally administered sitaxsentan